Dendreon

Dendreon's Infectious Influence on Biotechs

One of Thursday's hardest-hit stocks was Dendreon, maker of the prostate cancer vaccine Provenge, which plunged 67% after reporting disappointing results. But, weirdly, Debdreon's disease seemed to infect the entire sector, dragging down companies with proven drugs. Are biotechs bargains right now?

The Biggest Losers: 10 Stocks That Got Crushed

It's been heck of a ride on Wall Street: the ups, the downs, a 500-plus point selloff. But some stocks suffered far more than others this week. Here's a look at 10 of the biggest decliners.

Is ImmunoCellular Another Rising Star in Biotech?

Much like Dendreon, which has a promising prostate cancer drug, ImmunoCellular is developing a cancer drug. In this case, it battles brain cancer, and a Phase I trial turned in remarkable results. But unlike Dendreon, ImmunoCellular is still pretty much an unknown.

Is This Tiny Aussie Biotech the Next Dendreon?

Dendreon's Provenge, which targets prostate cancer, catapulted that company's stock to record highs recently. Prima Biomed's CVac works similarly, but it has the potential to target multiple forms of cancer, giving the Australian company an intriguing future.

Deutsche Bank Initiates Coverage of Biotech Stocks

Several biotech stocks were on the move Monday after Deutsche Bank initiated coverage on some of them. The bank's analyst, Robyn Karnauskas, took a generally wary view on the biotech sector, only putting buy ratings on Gilead and Dendreon.

Dendreon Shares Slide on Medicare Payment Worries

The stock sank on Thursday after the Centers for Medicare and Medicaid Services said it was evaluating data on Provenge, the company's prostate cancer vaccine, to decide whether to cover the drug for seniors nationwide.

Why Hot Biotech Dendreon Could Get Even Hotter

Dendreon is developing immunologically based drugs to fight cancer, and it's No. 1 drug is Provenge, which battles prostate cancer. The excitement is about whether Provenge finally gets the FDA's approval this year. If so, the stock could keep scoring.

Bad economic news squashes stocks

Investors dumped stocks today after a weak retail sales report and lower-than-expected producer price index data showing no inflation. The Dow Jones...